Patents by Inventor Gary Koppel

Gary Koppel has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Beta-lactamylalkanoic acids for treating premenstrual disorders
    Patent number: 9597314
    Abstract: 0-lactamyl alkanoic acids are described. Methods for treating various premenstrual disorders using or more ?-lactamyl alkanoic acids are also described.
    Type: Grant
    Filed: March 21, 2006
    Date of Patent: March 21, 2017
    Assignee: AZEVAN PHARMACEUTICALS, INC.
    Inventors: Gary A. Koppel, Marvin J. Miller
  • ?-lactamyl phenylalanine, cysteine, and serine vasopressin antagonists
    Patent number: 8426400
    Abstract: Substituted 2-(azetidin-2-on-1-yl)alkoxyalkylalkanoic acids and 2-(azetidin-2-on-1-yl)arylalkylalkanoic acids, and analogs and derivatives thereof are described. Methods for using the described compounds, and pharmaceutical compositions thereof, to treat disease states responsive to antagonism of one or more vasopressin receptors are also described.
    Type: Grant
    Filed: October 31, 2011
    Date of Patent: April 23, 2013
    Assignee: Azevan Pharmaceuticals, Inc.
    Inventors: Gary A. Koppel, Marvin J. Miller
  • BETA-LACTAMYL PHENYLALANINE, CYSTEINE, AND SERINE VASOPRESSIN ANTAGONISTS
    Publication number: 20120220765
    Abstract: Substituted 2-(azetidin-2-on-1-yl)alkoxyalkylalkanoic acids and 2-(azetidin-2-on-1-yl)arylalkylalkanoic acids, and analogs and derivatives thereof are described. Methods for using the described compounds, and pharmaceutical compositions thereof, to treat disease states responsive to antagonism of one or more vasopressin receptors are also described.
    Type: Application
    Filed: October 31, 2011
    Publication date: August 30, 2012
    Inventors: Gary A. KOPPEL, Marvin J. Miller
  • Beta-lactamyl phenylalanine, cysteine, and serine vasopressin antagonists
    Patent number: 8048874
    Abstract: Substituted 2-(azetidin-2-on-1-yl)alkoxyalkylalkanoic acids and 2-(azetidin-2-on-1-yl)arylalkylalkanoic acids, and analogs and derivatives thereof are described. Methods for using the described compounds, and pharmaceutical compositions thereof, to treat disease states responsive to antagonism of one or more vasopressin receptors are also described.
    Type: Grant
    Filed: July 18, 2006
    Date of Patent: November 1, 2011
    Assignee: Azevan Pharmaceuticals, Inc.
    Inventors: Gary A. Koppel, Marvin J. Miller
  • NEUROTHERAPEUTIC TREATMENT FOR SEXUAL DYSFUNCTION
    Publication number: 20110257147
    Abstract: A method for improving sexual function is described. A mammal suffering from sexual dysfunction or otherwise in need of enhanced sexual function is administered a compound selected from those that are capable of inhibiting the activity of ?-lactams, penicillin-binding protein, carboxypeptidase. Such compounds, including particularly ?-lactam ring-containing compounds, can be used to formulate pharmaceutical formulations useful for improving sexual function.
    Type: Application
    Filed: June 27, 2011
    Publication date: October 20, 2011
    Applicant: Revaax Pharmaceuticals, LLC
    Inventor: Gary A. Koppel
  • Neurotherapeutic treatment for sexual dysfunction
    Patent number: 7998991
    Abstract: A method for improving sexual function is described. A mammal suffering from sexual dysfunction or otherwise in need of enhanced sexual function is administered a compound selected from those that are capable of inhibiting the activity of ?-lactams, penicillin-binding proteins, and carboxypeptidases. Such compounds, including particularly ?-lactam ring-containing compounds, can be used to formulate pharmaceutical formulations useful for improving sexual function.
    Type: Grant
    Filed: November 21, 2006
    Date of Patent: August 16, 2011
    Assignee: Revaax Pharmaceuticals, LLC
    Inventor: Gary A. Koppel
  • Beta-LACTAMYL VASOPRESSIN V1a ANTAGONISTS
    Publication number: 20110059935
    Abstract: Novel 2-(azetidin-2-on-1-yl)alkanedioic acid derivatives and 2-(azetidin-2-on-1-yl)alkoxyalkanoic acid derivatives are described for use in the treatment of disease states responsive to antagonism of the vasopressin V1a receptor.
    Type: Application
    Filed: August 25, 2010
    Publication date: March 10, 2011
    Applicant: Azevan Pharmaceuticals, Inc
    Inventors: Robert F. Bruns, JR., Christophe D. G. Guillon, Ned D. Heindel, Gary A. Koppel, Marvin J. Miller
  • Neurotherapeutic Cephalosporin Sulfoxide and Sulfone-Containing Compositions
    Publication number: 20110046103
    Abstract: The treatment of neurological disorders using cefazolin compositions and pharmaceutical compositions including oral dosage forms that include cefazolin compositions are described.
    Type: Application
    Filed: November 3, 2010
    Publication date: February 24, 2011
    Applicant: Revaax Pharmaceuticals, LLC
    Inventors: Gary A. Koppel, Michael O. Chaney
  • Neurotherapeutic compositions and method
    Patent number: 7842683
    Abstract: Administration of ?-Lactam compounds, including ?-lactam antibiotics and ?-lactamase inhibitors provides significant neurotropic effects in warm-blooded vertebrates evidence inter alia by anxiolytic and anti-aggressive behavior modification and enhanced cognition. Therapeutic methods for using such compounds and their pharmaceutical formulations are described.
    Type: Grant
    Filed: January 23, 2008
    Date of Patent: November 30, 2010
    Assignee: Revaax Pharmaceuticals, LLC
    Inventor: Gary A. Koppel
  • Oral neurotherapeutic cephalosporin sulfoxide and sulfone-containing compositions
    Patent number: 7833998
    Abstract: The treatment of neurological disorders using cephalosporin sulfoxide-containing and/or cephalosporin sulfone-containing compositions and pharmaceutical compositions including oral dosage forms that include cephalosporin sulfoxide and/or sulfone-containing compositions are described.
    Type: Grant
    Filed: August 24, 2004
    Date of Patent: November 16, 2010
    Assignee: Revaax Pharmaceuticals, LLC
    Inventors: Gary A. Koppel, Michael O. Chaney
  • NEUROTHERAPEUTIC COMPOSITION AND METHOD THEREFOR
    Publication number: 20100249090
    Abstract: Neurotherapeutically effective pharmaceutical compositions are described that include carboxypeptidase E inhibitors. One class of carboxypeptidase E inhibitors found to exhibit significant neurotropic activity are ?-lactam compounds, particularly penam and cephem ?-lactam antibiotics and non-antibiotic derivatives thereof.
    Type: Application
    Filed: May 13, 2010
    Publication date: September 30, 2010
    Inventors: Gary A. Koppel, Michael O. Chaney
  • Neurotherapeutic compositions
    Publication number: 20100099656
    Abstract: Novel neuroprotectant compositions and methods are described. (?-Lactamase inhibitors are used to prevent or reduce loss of neuronal cells and neuronal cell function in patients afflicted with or susceptible to disease states or conditions known to result in or cause neuronal tissue insult.
    Type: Application
    Filed: December 18, 2009
    Publication date: April 22, 2010
    Inventor: Gary A. Koppel
  • BETA-LACTAM CANNABINOID RECEPTOR MODULATORS
    Publication number: 20100016274
    Abstract: Described herein are substituted 2-(azetidin-2-on-1-yl)alkanoic acids, alkanedioic acids and 2-hydroxyalkyl alkanoic acids, and 2-acyl alkanoic acids, and derivatives thereof, that are capable of modulating activity at the cannabinoid-1 (CB1) and/or cannabinoid-2 (CB2) receptor. Also described herein are methods for treating mammals in need of relief from disease states associated with and responsive to modulation of the CB1 and/or CB2 receptor activity.
    Type: Application
    Filed: September 14, 2007
    Publication date: January 21, 2010
    Inventors: Gary A. Koppel, Michael O. Chaney
  • BETA-LACTAMYLALKANOIC ACIDS FOR TREATING PREMENSTRUAL DISORDERS
    Publication number: 20090170825
    Abstract: 0-lactamyl alkanoic acids are described. Methods for treating various premenstrual disorders using or more O-lactamyl alkanoic acids are also described.
    Type: Application
    Filed: March 21, 2006
    Publication date: July 2, 2009
    Inventors: Gary A. Koppel, Marvin J. Miller
  • Beta-Lactamyl Phenylalanine, Cysteine, and Serine Vasopressin Antagonists
    Publication number: 20080280870
    Abstract: Substituted 2-(azetidin-2-on-1-yl)alkoxyalkylalkanoic acids and 2-(azetidin-2-on-1-yl)arylalkylalkanoic acids, and analogs and derivatives thereof are described. Methods for using the described compounds, and pharmaceutical compositions thereof, to treat disease states responsive to antagonism of one or more vasopressin receptors are also described.
    Type: Application
    Filed: July 18, 2006
    Publication date: November 13, 2008
    Inventors: Gary A. Koppel, Marvin J. Miller
  • Neurotherapeutic Compositions and Method
    Publication number: 20080200447
    Abstract: Administration of ?-Lactam compounds, including ?-lactam antibiotics and ?-lactamase inhibitors provides significant neurotropic effects in warm-blooded vertebrates evidence inter alia by anxiolytic and anti-aggressive behavior modification and enhanced cognition. Therapeutic methods for using such compounds and their pharmaceutical formulations are described.
    Type: Application
    Filed: January 23, 2008
    Publication date: August 21, 2008
    Applicant: REVAAX PHARMACEUTICALS, LLC
    Inventor: Gary A. Koppel
  • Oral Neurotherapeutic Cefazolin Compositons
    Publication number: 20080176825
    Abstract: The treatment of neurological disorders using cefazolin compositions and pharmaceutical compositions including oral dosage forms that include cefazolin compositions are described.
    Type: Application
    Filed: August 24, 2004
    Publication date: July 24, 2008
    Inventors: Gary A. Koppel, Michael O. Chaney
  • {Beta}-Lactamyl vasopression V1a antagonists and methods of use
    Publication number: 20080113959
    Abstract: Novel 2-(azetidin-2-on-1-yl) alkanedioic acid derivatives and 2-(azetidin-2-on-1-yl) alkoxyalkanoic acid derivatives are described for use in the treatment of disease states responsive to antagonism of the vasopressin V1a receptor.
    Type: Application
    Filed: October 17, 2007
    Publication date: May 15, 2008
    Applicant: Azevan Pharmaceuticals, Inc.
    Inventor: Gary Koppel
  • {Beta}-Lactamyl vasopression V1a antagonists and methods of use
    Publication number: 20080090797
    Abstract: Novel 2-(azetidin-2-on-1-yl)alkanedioic acid derivatives and 2-(azetidin-2-on-1-yl)alkoxyalkanoic acid derivatives are described for use in the treatment of disease states responsive to antagonism of the vasopressin V1a receptor.
    Type: Application
    Filed: October 17, 2007
    Publication date: April 17, 2008
    Applicant: Azevan Pharmaceuticals, Inc.
    Inventors: Gary Koppel, Robert Bruns
  • [Beta]-Lactamyl Vasopressin V1a Antagonists and Methods of Use
    Publication number: 20080033165
    Abstract: Novel 2-(azetidin-2-on-1-yl) alkanedioic acid derivativies and 2-(azetidin-2-on-1-yl) alkoxyalkanoic acid derivativies are described for use in the treatment of disease states responsive to antagonism of the vasopressin V1a receptor.
    Type: Application
    Filed: August 7, 2007
    Publication date: February 7, 2008
    Inventors: Gary Koppel, Robert Bruns